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Abstract Thymosin L-10 (TB10) is a small G-actin binding
protein that induces depolymerization of intracellular F-actin
pools by sequestering actin monomers. Previously, we demon-
strated that overexpression of TB10 in ovarian tumor cells in-
creased the rate of cell death. As an initial step to de¢ne mo-
lecular mechanism of TB10-dependent apoptotic process in
ovarian tumor cells, we searched a human ovary cDNA library
for a novel TB10 binding protein using a yeast two-hybrid sys-
tem. The selected protein was human E-tropomodulin (E-
Tmod), another component of the actin binding proteins. Sub-
sequently, two interacting protein components were determined
quantitatively. Results showed that the full-length TB10 is re-
quired to bind with E-Tmod, and the TB10 binding site on E-
Tmod partially overlaps with the actin binding site on E-Tmod.
Moreover, introduction of E-Tmod cDNA into a tumor cell line
reversed TB10 mediated apoptosis and restored actin architec-
tures. These results may suggest that TB10 regulates apoptotic
homeostasis by not only just binding to actin but also competing
or blocking the protein complex formation of E-Tmod with
actin.
/ 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Actin is one of the primary proteins that are responsible for
maintaining the structure of most eukaryotic cytoskeletons [1].
The dynamic equilibrium between monomeric G-actin and F-
actin regulates many cellular functions ranging from mitosis
to motility. It is clear that such functions depend on the tight
control of actin polymerization by actin monomer sequester-
ing proteins. The L-thymosins are a family of highly conserved
polar 5 kDa peptides. Both in vitro and in vivo studies in-
dicate that they bind monomeric G-actin and prevent actin
polymerization into F-actin in the cytoplasm of non-muscle
cells [2].
Thymosin L-10 (TB10) is a 5 kDa polypeptide comprised of
43 amino acid residues containing an unusual acetylated ala-
nine as the ¢rst amino acid residue in a mature peptide [2].
TB10 and thymosin L-4 (TB4), another member of the thy-
mosin family, are major G-actin sequestering proteins in
mammalian tissues. Depending on the concentration of
TB10 or TB4, intracellular F-actin networks are selectively
increased or decreased [3^5].
Two critical outcomes for mammalian cells may be a¡ected
by the action of TB10: programmed cell death [6] and meta-
stasis [7]. In human carcinogenesis, the L-thymosins bind and
sequester G-actin, which plays a pivotal role in maintaining
the cellular cytoskeleton. The perturbed balance between
monomeric G- and F-actin in transformed cells alters the
motility and adhesion processes that are important in tumor
progression and metastasis formation as well as apoptosis.
Whereas TB10 may contribute to invasion or metastasis in
some cancer types, we demonstrated its involvement in apo-
ptosis of ovarian tissue [8]. Overexpression of TB10 in ovarian
tumor cells increased the rate of cell death [8]. Similar to this
observation, thymosin L-9 overexpression also altered the lev-
el of apoptosis in infected bovine macrophages [9].
To begin characterization of the TB10-dependent apoptotic
pathway, we used a yeast two-hybrid system to screen a hu-
man ovary cDNA library for novel TB10 binding proteins.
We identi¢ed human E-tropomodulin (E-Tmod), another
component of the actin binding proteins. Interestingly, TB10
and actin share the same binding site on E-Tmod. Transient
transfection analyses demonstrated that increased E-Tmod ex-
pression e⁄ciently blocks the TB10-dependent apoptotic ac-
tivity. Therefore, these results support that a dynamic equilib-
rium among pools of actin, TB10 and E-Tmod regulates an
apoptotic homeostasis.
2. Materials and methods
2.1. Yeast two-hybrid screening
For bait construction with human TB10, cDNA encoding full-
length human TB10 (Met31-Ser43) was subcloned into the EcoRI
and SalI restriction sites of the pGilda. The resulting plasmid pGil-
da-TB10 was introduced into yeast strain EGY48 [MATa, his3, trp1,
ura3-52, leu2: :pLeu2-LexAop6/pSH18-34 (LexAop-lacZ reporter)] by
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a modi¢ed lithium acetate method [10]. The ovary cDNA library was
constructed by cloning the cDNA fragments into the EcoRI and XhoI
restriction sites of the pJG4-5 to generate B42 fusion proteins (Clon-
tech, Palo Alto, CA, USA). The cDNAs encoding B42 fusion proteins
were introduced into the competent yeast cells that already contained
pGilda-TB10 and the transformants were selected for the tryptophan
prototrophy (plasmid marker) on synthetic medium (Ura3, His3,
Trp3) containing 2% glucose.
2.2. Quantitation of interaction
The activity of the interaction between TB10 and E-Tmod was
compared by measuring the relative expression level of L-galactosi-
dase. The L-galactosidase assay was determined according to the pre-
viously described method [11] with slight modi¢cation. Brie£y, yeast
cells (EGY48 strain) containing each construct were cultured in yeast
synthetic media (Ura3, His3, Trp3) with 2% glucose until they
reached the mid-log phase. Then, the cells were transferred in a yeast
medium (Ura3, His3, Trp3) containing 2% galactose and 0.2%
Me2SO. Equivalent numbers of cells were lysed in 0.7 ml Z bu¡er
(60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4,
and 50 mM L-mercaptoethanol, pH 7.0) containing 50 Wl 0.1% sodium
dodecyl sulfate (SDS) and 50 Wl chloroform for 30 s at 30‡C. Then, L-
galactosidase activity was measured by adding 140 Wl of 4 mg/ml o-
nitrophenyl L-D-galactopyranoside (ONPG). The reaction was carried
out at 30‡C until yellow color appeared, and then quenched by adding
0.4 ml of 1 M Na2CO3. The samples were centrifuged brie£y to re-
move cell debris, and the absorbance was measured at 420 and 550
nm. The L-galactosidase activity was calculated using the formula
units = [1000U(A42031.75UA550)]/(timeUvolumeUA600).
2.3. In vitro pull-down assay
cDNA encoding human TB10 was subcloned into the EcoRI and
XhoI restriction sites of the pGEX4T-1 (Amersham Biosciences, Upp-
sala, Sweden) to generate glutathione S-transferase (GST) fusion pro-
tein (GST-TB10). The human E-Tmod and actin cDNA were ligated
into pET29a (Novagen, Madison, WI, USA) using EcoRI and XhoI to
generate a histidine fusion protein (His-E-Tmod and His-actin). GST
and histidine fusion proteins were puri¢ed using either GST column
(Amersham) or Ni2þ column (Invitrogen Life Technologies, Carlsbad,
CA, USA) according to the manufacturer’s protocols. The puri¢ed
GST-TB10 (2 Wg) was mixed either with His-E-Tmod (2 Wg) or with
His-actin (2 Wg), or both of them. The mixtures were then added to 20
Wl of GST column matrix (glutathione Sepharose 4B) and incubated
at 25‡C for 30 min. The slurry was pelleted by centrifugation and
washed. The pellet of the gel matrix was resuspended in 20 Wl elution
bu¡er (10 mM glutathione, 50 mM Tris^HCl, pH 8.0) and incubated
at 25‡C for 20 min to elute the bound GST fusion proteins. The eluted
proteins were separated by gel electrophoresis and the proteins were
detected by Coomassie staining.
2.4. Subcloning of deletion mutants of TB10 and E-Tmod
Two deletion mutants (v-1^28 and v29^43) of TB10 were isolated
by polymerase chain reaction (PCR) using the combination of the
following primers (TB-F1, 5P-ATTGAATTCATGGCAGACAAA-
CCAGAC-3P ; TB-R1, 5P-ATTCTCGAGTTACAGGGTGTTCTTC-
TC-3P ; TB-F2, 5P-CCGGAATTCCCGACCAAAGAGACCATT-3P ;
TB-R2, 5P-CCGCTCGAGTTAGGAAATTTCACTCCG-3P). PCR
products spanning each fragment were cloned into the EcoRI and
XhoI restriction sites of the pGilda.
Three deletion mutants (v1^161, v1^230 and v1^310) of E-Tmod
were isolated by PCR using the combination of the following primers
(E-Tmod-F1, 5P-CCGGAATCACGATGTCGTACAGACGAGAAC-
3P ; E-Tmod-F2, 5P-CCGGAATTCAACAGCGTGATTAAACCCA-
CA-3P ; E-Tmod-F3, 5P-CCGGAATTCATCGTGGGGACACGGA-
GTAAT-3P ; E-Tmod-F4, 5P-CCGGAATTCACACTTCTCAAATTC-
GGCTAC-3P ; E-Tmod-R1, 5P-CCGCTCGAGCTAGACACCACTC-
CGGCACTT-3P). PCR products spanning each fragment were cloned
into the EcoRI and XhoI restriction sites of the pJG4-5. Each con-
structed plasmid was introduced into yeast EGY48 expressing either
E-Tmod or TB10 hybrid protein.
2.5. Co-immunoprecipitation
cDNA encoding human TB10 (Met31-Ser43) was isolated by PCR
by using the speci¢c template and then cloned into pEGFPC1 (Clon-
tech) digested with BglII and EcoRI (pEGFPC1-TB10). The human
E-Tmod cDNA (Met1-Val359) was ligated into pcDNA4/HisMax (In-
vitrogen) using EcoRI and XhoI (pcDNA4/HisMax-E-Tmod). For co-
immunoprecipitation, SKOV-3 ovarian cancer cells were co-trans-
fected with cDNA constructs of pEGFPC1-TB10 and pcDNA4/His-
Max-E-Tmod using FuGENE6 (Roche Applied Science, Basel, Swit-
zerland). As a negative control, pEGFPC1-TB10 and empty vector
pcDNA4/HisMax was also co-transfected. Three days after transfec-
tion, cells were harvested by trypsinization and centrifugation. Cell
pellets were washed in phosphate bu¡ered saline (PBS), resuspended
in cell lysis solution (50 mM Tris, pH 7.2, 150 mM NaCl, 1% Triton
X-100, 1 Wg/ml leupeptin, 1 Wg/ml pepstatin, 2 Wg/ml aprotinin, 200
Wg/ml phenylmethylsulfonyl £uoride). Lysates were incubated with
anti-GFP antibody (Zymed) and precipitated with protein A-agarose.
The precipitated proteins were resolved by SDS gel electrophoresis,
transferred onto Immobilon P membrane (Millipore), and immuno-
blotted with anti-His antibody (Amersham) or rabbit anti-TB10 anti-
serum using the ECL system (Amersham).
2.6. Cell viability assay
SKOV-3 ovarian cancer cells were plated in six-well plates and co-
transfected with di¡erent ratios of human TB10 and human E-Tmod
cDNAs. Three days after transfection, cells were harvested, stained
with trypan blue, and counted under the light microscope.
2.7. Apoptosis assay
SKOV-3 ovarian cancer cells were plated onto four-chamber slides
and co-transfected with human TB10 and human E-Tmod cDNAs at
ratio 1:1. Three days after transfection, chamber slides were rinsed
with PBS, stained with 2 mg/ml of DAPI (Boehringer Mannheim,
Mannheim, Germany) at 37‡C for 15 min, washed twice with PBS
and examined with the £uorescence microscope.
2.8. Fluorescence detection of F-actin
Cell monolayers were ¢xed for 40 min at room temperature with
4% paraformaldehyde in PBS and then stained with 25 Wl/ml of phal-
loidin-FITC (Sigma, St. Louis, MO, USA) for 1 h in the dark. Stained
cell monolayers were washed twice with 0.5% Triton X-100 in PBS.
After washing, coverslips were mounted onto slides using a PBS/gly-
cine mutant and examined with the £uorescence microscope.
3. Results
3.1. Identi¢cation of E-Tmod as a TB10 binding protein
The human ovary cDNA library fused to the gene for the
transcription activator pJG4-5 was introduced into yeast cells
containing the pGilda-TB10 (Met31-Ser43) as bait. Approxi-
mately 3U106 independent transformants were pooled and
respread on the selection media (Ura3, His3, Trp3, Leu3)
containing 2% galactose to induce the expression of cDNA.
If a B42 tagged protein interacts with the TB10, it will activate
the transcription of LEU2 gene and allow the host cells to
grow on a synthetic medium lacking leucine. Among 15 col-
onies obtained on the selection media, a total of eight colonies
showed galactose dependency. The plasmids were isolated
from the selected yeast cells and introduced into Escherichia
coli KC8 to isolate the plasmids carrying pJG4-5-cDNA in-
serts. The plasmids were then isolated by the plasmid marker
trp in the E. coli host, and the puri¢ed plasmids were se-
quenced. A homology search in the GenBank using the
BLAST program revealed that seven out of eight plasmids
encoded E-Tmod. All of E-Tmod encoded plasmids contained
a cDNA with 100% identity to the 291 amino acid C-terminal
sequence of human E-Tmod (GenBank accession number:
BC016731; Leu68-Val359 ; Fig. 1A). One positive plasmid
was encoded human eukaryotic transcription factor 1-Q (Gen-
Bank accession number: BT006677).
The interaction between TB10 and E-Tmod was further
examined by GST pull-down analysis and co-immunoprecip-
itation. For GST pull-down analysis, the GST-TB10 fusion
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protein was mixed either with His-E-Tmod or with His-actin
or both of them, the mixture was puri¢ed employing GST
column matrix. The eluted proteins were separated by gel
electrophoresis and the proteins were detected by Coomassie
staining. As shown in Fig. 1B, GST-TB10 was co-puri¢ed
with both His-E-Tmod and His-actin at approximately 1:1
molar ratio (lanes 4 and 5). When we mixed GST-TB10
with both His-E-Tmod and His-actin, we observed that all
three proteins were associated, but amount of co-puri¢ed E-
Tmod and actin by GST column matrix (lane 6) was relatively
lower compared to that of E-Tmod with TB10 (lane 4) or that
of actin with TB10 (lane 5). The molar ratio between co-pu-
ri¢ed E-Tmod and actin was at approximately 1:1 ratio in
lane 6. This result may indicate that E-Tmod and actin com-
Fig. 1. Interaction analysis between human E-Tmod and TB10. A: The amino acid sequence of E-Tmod indicated using single letter abbrevia-
tions. The underlined amino acid sequence means the translated E-Tmod protein isolated from yeast two-hybrid screening. B: Interactions be-
tween TB10 (GST-TB10), E-Tmod (His-E-Tmod) and actin (His-actin) were con¢rmed by in vitro pull-down assays. For GST pull-down analy-
sis, the puri¢ed GST-TB10 (2 Wg) was mixed with either His-E-Tmod (2 Wg) or His-actin (2 Wg), or both of them. Then, the protein mixtures
were subjected to GST a⁄nity puri¢cation. The eluted proteins were separated by gel electrophoresis and the proteins were detected by Coo-
massie staining. Lanes: 1, GST-TB10; 2, His-E-Tmod; 3, His-actin; 4, GST-TB10 and His-E-Tmod; 5, GST-TB10 and His-actin; 6, GST-
TB10, His-Tmod, and His-actin, respectively. C: Co-immunoprecipitation of TB-10 with E-Tmod. Lanes: 1, lysate from pEGFPC1-TB10 and
pcDNA4/HisMax (vector only) co-transfectant; 2, lysate from pEGFPC1-TB10 and pcDNA4/HisMax-E-Tmod co-transfectant. IP means immu-
noprecipitation and WB means immunoblotting with indicated antibodies.
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petitively bind to TB10. As positive controls, GST-TB10 (lane
1), His-E-Tmod (lane 2) and His-actin (lane 3) were puri¢ed
using either GST column matrix or Ni2þ column and loaded,
200 ng each, on the gel. This result indicated that all of the
three proteins form a complex, but the binding strength of
each protein interaction remained to be determined.
For co-immunoprecipitation, cDNA constructs of TB10
(pEGFPC1-TB10) and E-Tmod (pcDNA4/HisMax-E-Tmod),
or pEGFPC1-TB10 and pcDNA4/HisMax (vector only) were
co-transfected into SKOV-3 ovarian cancer cells. Subse-
quently, an immunoprecipitation was performed using anti-
GFP antibody with lysates from both transfected cells. After
immunoprecipitation, the precipitated proteins were immuno-
blotted using anti-His antibody or anti-TB10 antibody. As
shown in Fig. 1C, pcDNA4/HisMax-E-Tmod was co-immu-
noprecipitated with pEGFPC1-TB10 (lane 2 in the upper pan-
el), whereas no interaction was observed between pcDNA4/
HisMax (vector only) and pEGFPC1-TB10 (lane 1 in the
upper panel). An immunoblotting using anti-TB10 antibody
con¢rmed that an equal amount of TB10 was precipitated in
both samples (middle panel). Whole cell lysates from both
samples contained the equivalent proteins when we immuno-
blotted using anti-L-actin antibody (lower panel).
3.2. Mapping of the interaction region between human TB10
and human E-Tmod
To identify the E-Tmod binding region of TB10, cDNA
constructs containing two TB10 deletion mutants were de-
signed as shown in Fig. 2A. These truncated regions were
predicted to be predominantly K-helices. One deletion mutant
Fig. 2. Mapping the region of TB10 for interaction with E-Tmod. A: Schematic representation of cDNA constructs for each TB10 deletion
mutant and full-length human TB10 fusion proteins in the yeast two-hybrid system. B: cDNA constructs were co-transformed into EGY48
yeast cells to test the protein^protein interaction within the yeast two-hybrid system. C: Binding activity of these constructs by ONPG assays.
The results are representative of three separate experiments. Data are shown as meanUS.E.M.
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(v-1^28) does not contain the LKKTET motif that is common
to L-thymosins. These regions were shown to be responsible
for binding actin [12]. Another deletion (v29^43) mutant con-
tains the LKKTET motif.
In the two-hybrid system, the full-length human E-Tmod
cDNA and either plasmid containing a full-length human
TB10 cDNA (Fig. 2A, Full) or plasmids containing two trun-
cation mutant forms (Fig. 2A, v-1^28 and v29^43) of cDNAs
were co-transformed into EGY48 yeast cells. Cells containing
only full-length TB10 cDNA construct grew on the Ura, His,
Trp and Leu de¢cient plates, whereas yeast cells transformed
with both deletion mutant colonies (v-1^28 and v29^43) failed
to grow (Fig. 2B). To con¢rm this result, we determined the
binding activity of these constructs by measuring the relative
expression level of L-galactosidase. As shown in Fig. 2C, L-
galactosidase assay results con¢rmed that either of these mu-
tants cannot bind to E-Tmod. However, we cannot exclude
that the E-Tmod binding site of TB10 is located near the
junction of two K-helices.
Subsequently, cDNA constructs containing three E-Tmod
truncation mutants were designed to localize the TB10 bind-
ing region of E-Tmod (Fig. 3A). These truncated regions were
predicted to be predominantly K-helices. In the two-hybrid
system, full-length human TB10 cDNA and either full-length
human E-Tmod cDNA (Fig. 3A, Full) or three truncation
mutants (Fig. 3A, v1^161, v1^230 and v1^310) were co-trans-
formed into EGY48 yeast cells. Cells containing full-length E-
Tmod cDNA and also the smallest deletion mutant (v1^161)
grew on the Ura, His, Trp and Leu de¢cient plates. Yeast cells
transformed with the other deletion mutants (v1^230 and v1^
310) failed to grow (Fig. 3B). We also quantitated the binding
activity of these constructs by measuring relative expression
level of L-galactosidase. Consistent with Fig. 3B, the critical
E-Tmod regions for binding TB10 resided within Asn162 and
Fig. 3. Mapping of the E-Tmod interaction region with TB10 using the yeast two-hybrid system. A: Schematic representation of cDNA con-
structs for each human E-Tmod deletion mutant and full-length human E-Tmod fusion proteins in the yeast two-hybrid system. B: cDNA con-
structs were co-transformed into EGY48 yeast cells to test the protein^protein interaction within the yeast two-hybrid system. C: Binding activ-
ity of these constructs by ONPG assays. The results are representative of three separate experiments. Data are shown as meanUS.E.M.
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Ser230 (Fig. 3C). The L-galactosidase activity for interactions
between TB10 and one partial deleted mutant of E-Tmod
(v1^161) was lower than that of full-length E-Tmod. This
may indicate that the region between Met1-Leu161 of E-
Tmod enhances TB10 binding, but is not critical.
3.3. E-Tmod rescues tumor cells from TB10 mediated apoptosis
by restoring actin architecture
Since the TB10 binding site of E-Tmod (Asn162-Ser230) par-
tially overlaps with the actin binding site of E-Tmod (Ile190
and Val359), we tried to block TB10 mediated apoptosis by
introducing the full-length E-Tmod cDNA. SKOV-3 ovarian
cancer cell line was grown in DMEM and co-transfected with
di¡erent ratios of TB10 and E-Tmod cDNAs (Fig. 4A). Three
days after transfection, the cells were harvested, stained with
trypan blue and quantitated to analyze cell viability. Mock
transfectants include the expression vector only and control
indicates cells without transfection. Viability of the transfec-
tant containing only TB10 was very low compared to that of
the mock transfection or control, indicating that this trans-
fectant undergoes vivid apoptosis (Fig. 4A, left). However,
viability of the transfectant containing only E-Tmod was
very similar to that of the mock transfectant or control, sup-
porting that E-Tmod did not a¡ect apoptotic process (Fig.
4A, left). Co-transfection with TB10 (5 Wg) and E-Tmod
cDNA (5 Wg) at a ratio of 1:1 signi¢cantly decreased apopto-
sis compared to that of transfectant containing only TB10
(Fig. 4A, right). Furthermore, co-transfection with TB10 (5
Wg) and E-Tmod cDNAs (2.5 and 1 Wg) at higher ratios of 2:1
and 5:1 correlated with increased apoptosis (Fig. 4A, right).
Also, co-transfection with TB10 (2.5 and 1 Wg) and E-Tmod
cDNAs (5 Wg) at ratios of 1:2 and 1:5 gradually decreased
apoptosis (Fig. 4A, right). These combined results suggest
that E-Tmod expression e⁄ciently blocks TB10 mediated ap-
optosis.
We also stained with DAPI to con¢rm that the loss of
viability is due to apoptosis. Transfectants containing only
TB10 cDNA showed clear DNA fragmentations, whereas ei-
ther mock transfectants or transfectant containing only E-
Tmod cDNA did not show any signs of DNA fragmentation
(Fig. 4B). In agreement with cell viability assay, co-transfec-
tant with TB10 and E-Tmod cDNAs at a ratio of 1:1 clearly
decreased DNA fragmentation compared to that of transfec-
tant containing only TB10 (Fig. 4B).
Further, we performed phalloidin staining assays on
SKOV-3 ovarian cancer cells to analyze the e¡ect of E-
Tmod on TB10 mediated apoptosis. As shown in Fig. 4C,
staining with phalloidin-FITC revealed the presence of an
intact and pervasive actin structure in control and E-Tmod
transfected cells, whereas overexpression of TB10 dramatically
disrupted the F-actin stress ¢bers. Strikingly, E-Tmod and
TB10 overexpressed cells restore the actin architecture almost
similarly to mock and E-Tmod transfected cells. This is clear
evidence that the interaction between E-Tmod and TB10 res-
cues cells from TB10 mediated apoptosis by restoring actin
architecture.
4. Discussion
We identi¢ed E-Tmod, a component of the actin complex,
as a novel TB10 binding protein. The interaction between
TB10 and E-Tmod could be the ¢rst example of a regulation
mechanism of thymosin-L proteins which may have a role in
preventing apoptosis.
E-Tmod is the P-end (pointed or slow growing end) capping
protein that modulates the actin binding proteins to control
the length of the actin ¢lament [13^15]. Blocking the E-Tmod
capping activity in cultured myocytes results in an abnormal
assembly of the actin architecture [13,16].
Biochemical analysis of E-Tmod revealed two functional
domains of E-Tmod. One is the N-terminal half that is pre-
dicted to be elongated and £exible [17]. The £exible and ex-
tended conformation of the N-terminus between Glu6 and
Val184 may be required for the direct interaction of E-Tmod
with tropomyosin [18]. The C-terminal half between Ile190 and
Val359 is proposed to be compact and tightly folded and in-
volved in the capping activity to actin [17,19]. Although the
details of the E-Tmod^tropomyosin interaction have not been
clari¢ed, the interaction site of E-Tmod is dependent on the
type of target tropomyosin. Interestingly, the region from
amino acids Glu6 to Lys94 of E-Tmod interacts with skeletal
muscle tropomyosin, whereas the region from Glu90 to Glu184
interacts with erythrocyte tropomyosin [20]. Our results on the
E-Tmod binding assay with TB10 using the yeast two-hybrid
Fig. 4. E-Tmod rescues TB10 mediated apoptosis by restoring actin
architecture. Cell viability assay (A), apoptosis assay (B) and phal-
loidin staining (C) were performed on SKOV-3 ovarian cancer cells
transfected with TB10 and/or E-Tmod. The results are representa-
tive of three separate experiments. A: Cells were stained with trypan
blue and quantitated to analyze cell viability. Data are shown as
meanUS.E.M. B: Cells were stained with DAPI to visualize DNA
fragmentations for the apoptosis assay. Arrows indicate the ob-
served DNA fragmentations. Size bar, 20 Wm. C: Cells were stained
with phalloidin-FITC to visualize F-actin networks. Mock means
cells transfected empty expression vector and control means those
without transfection. Size bar, 20 Wm.
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system revealed that the critical E-Tmod regions for binding
TB10 resided within Asn162 and Ser230. This region is partially
overlapped with the actin binding site.
To determine which TB10 regions are required for the in-
teraction with E-Tmod, we constructed two deletion mutants
and tested them using the yeast two-hybrid system. TB10 is
composed of two K-helices and we have tried to test whether
two helices are important for its binding with E-Tmod. One
deletion mutant (v-1^28) does not contain the LKKTET mo-
tif that is common to L-thymosins [21]. These regions were
shown to be responsible for binding actin [21]. Another dele-
tion (v29^43) mutant contains the LKKTET motif. Thus, our
results revealed that both helices appear to be required for the
interaction.
It has been suggested that the cytoskeleton is involved in
the morphological changes associated with apoptosis. Consis-
tent with this, reorganization of the micro¢lament network is
necessary to form apoptotic bodies. In addition, depolymeri-
zation of F-actin may also be a necessary component of the
apoptotic process. Thus, it is not surprising that actin associ-
ated proteins could be involved in the apoptotic process. For
example, cleavage of actin modulating proteins such as fodrin
and gelsolin by interleukin-I converting (ICE) or ICE-like
protease during the apoptotic process presumably alters the
homeostasis of the actin polymerization status [22^24].
Herein, we showed another example of an actin binding
protein modulating the apoptotic process. The fact that
TB10 shares the same binding site for E-Tmod (Asn162 to
Ser230) as for actin may explain how TB10 overexpressing cells
undergo apoptosis. Overexpression of TB10 could bind to E-
Tmod and prevent an interaction between E-Tmod and actin.
In the absence of available E-Tmod, the actin complex would
become unstable, resulting in the disruption of the cytoskele-
tal architecture. Supporting this idea, we have shown that co-
transfection with E-Tmod and TB10 into ovarian cancer cells
restores actin architecture, whereas transfection with TB10
alone disrupts the actin architecture. Also, varying the relative
ratios of TB10 and E-Tmod cDNA in transfected cells mod-
ulates cell viability.
In summary, we have identi¢ed E-Tmod as a novel binding
partner for TB10 via yeast two-hybrid screening. We have
also mapped the critical molecular domains required for this
interaction. Finally, transfection experiments indicate that
TB10 may bind E-Tmod to prevent the actin ¢lament complex
and induce an apoptotic process. These combined results sug-
gest that TB10 may have an important biological role in reg-
ulating E-Tmod function and possibly in targeting E-Tmod to
the actin complex where it could participate in the regulation
of the apoptotic process.
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